Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine/Cedazuridine + Defactinib in MDS, AML, and CMML
NCT05636514Phase 1Recruiting
- Sponsor
- Clinical Hub for Interventional Research
- Start
- Dec 2022
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of defactinib in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML), sponsored by Clinical Hub for Interventional Research. Primary endpoint: Maximum tolerated dose at 2 months. Started Dec 2022; status: recruiting.
02
Drugs
defactinib
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT05636514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05636514.